The Team

Satish Chandran, Ph.D.

Currently, Satish Chandran is the Chief Executive Officer of Somahlution, Global Pharma Analytics and Akshaya Bio. Dr. Chandran is a biotechnology veteran entrepreneur and has held significant leadership positions over the last 25 years. Until recently, Dr. Chandran was the Director of the Center of Excellence for Biopharmaceutical Research & Development, and Professor of Pharmaceutics at North Dakota State University.

Prior to that, Dr. Chandran was the Chief Technology Officer at the OTU in the BioTx Division at Pfizer, in Cambridge, MA. Previous to Pfizer, he was a Professor at the Institute for Hepatitis and Virus Research in Doylestown, PA, and was the Chief Operating Officer and Chief scientific Officer at Nucleonics, a company that he cofounded while on the faculty at Thomas Jefferson University’s Biochemistry Department.

Prior to founding Nucleonics Dr. Chandran headed up the DNA Vaccine Division of Wyeth-Lederle Vaccines, following acquisition of Apollon, a biotech company in Malvern, PA, focused on advancing DNA vaccine-based product candidates for infectious diseases and cancer.

Dr. Chandran received his Ph.D. from Memorial University in Newfoundland, Canada and completed a post-doctoral fellowship at Fox Chase Cancer Center in Philadelphia. He is a strategic consultant and a member of the Board of Directors for several emerging and established biotechnology companies.

Catherine Pachuk, Ph.D.

Dr. Pachuk is the Chief Scientific Officer of Somahlution and is a member of the Company’s Board of Directors. Dr. Pachuk has twenty years R&D leadership experience in the pharmaceutical and biotech sectors with expertise in drugs, biologics and vaccine development. She was involved in advancing multiple product candidates into the clinic.

Dr. Pachuk began her biotech career with Apollon, Inc. developing oligonucleotide-based therapeutics, and DNA-based vaccines. Following the acquisition of Apollon, Inc. by Wyeth-Ayerst Research in 1998 she advanced several products into clinical trials.

In 2001 she co-founded Nucleonics, a biotech focused on the development of RNAi-based therapeutics, where she was VP of Preclinical Research. Prior to joining Somahlution, Dr. Pachuk led biology efforts for Pfizer’s OTU in the BioTx Division in the areas of oncology and metabolic disease and was a member of the Executive Leadership Team.

Dr. Pachuk received her Ph.D. in molecular virology from the University of Pennsylvania and completed a post-doctoral fellowship at SmithKline Beecham.

Andrew B. Peltzman, JD, MBA.

Andrew Peltzman serves as principal administrator of Veritas ownership group, and concentrates his efforts on assisting Veritas’s various support teams in advancing Veritas’s goals and strategic plan. He often is directly involved in working with Veritas’s licensees, attorneys, and support personnel to develop and manage Veritas opportunities and relationships.

Mr. Peltzman’s background includes various entrepreneurial and business ventures.  Among others, he was the founder of a medical publication and acted as its Publisher for many years, and he also co-developed a nationally recognized sports tour operation. Mr. Peltzman has provided consulting services to numerous businesses, both publicly and privately held; primarily in the areas of market/business development, strategic planning, and business plan development.

Mr. Peltzman is also a practicing attorney, admitted to practice before the Supreme Court of Pennsylvania. He graduated with honors, Cum Laude from Widener University School of Law, and also holds an MBA degree from Drexel University. Mr. Peltzman performed his undergraduate studies at American University. Mr. Peltzman has received several awards; most notably he was awarded an “Achievement of Excellence” award while at Widener.